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Megakaryocytes  are  specialized  mammalian 
cells responsible for the production of blood 
platelets. The latter are generated by an extraor-
dinary  feat  of  cellular  remodeling  (Italiano   
et al., 1999; Patel et al., 2005; Junt et al., 2007). 
Massive cytoskeletal rearrangements drive the 
formation of cytoplasmic extensions called pro-
platelets,  structures  along  which  large-scale 
trafficking  of  granules  and  organelles  occurs. 
These components are packaged into nascent 
platelets, which are then released from the BM 
into the circulation. Effectively the entire cyto-
plasm of a megakaryocyte is converted in this 
manner, each giving rise to hundreds, or poten-
tially thousands, of platelets.
It is widely held that to produce platelets, 
megakaryocytes deliberately activate apoptosis 
(Kaluzhny and Ravid, 2004; Fadeel and Orrenius, 
2005; Patel et al., 2005; Siegel, 2006; Galluzzi 
et al., 2008; Solary et al., 2008). A considerable 
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It is believed that megakaryocytes undergo a specialized form of apoptosis to shed plate-
lets. Conversely, a range of pathophysiological insults, including chemotherapy, are thought 
to cause thrombocytopenia by inducing the apoptotic death of megakaryocytes and  
their progenitors. To resolve this paradox, we generated mice with hematopoietic- or 
megakaryocyte-specific deletions of the essential mediators of apoptosis, Bak and Bax.  
We found that platelet production was unperturbed. In stark contrast, deletion of the prosur-
vival protein Bcl-xL resulted in megakaryocyte apoptosis and a failure of platelet shedding. 
This could be rescued by deletion of Bak and Bax. We examined the effect on megakaryo-
cytes of three agents that activate the intrinsic apoptosis pathway in other cell types: 
etoposide, staurosporine, and the BH3 mimetic ABT-737. All three triggered mitochondrial 
damage, caspase activation, and cell death. Deletion of Bak and Bax rendered megakaryo-
cytes resistant to etoposide and ABT-737. In vivo, mice with a Bak/ Bax/ hemato-
poietic system were protected against thrombocytopenia induced by the chemotherapeutic 
agent carboplatin. Thus, megakaryocytes do not activate the intrinsic pathway to generate 
platelets; rather, the opposite is true: they must restrain it to survive and progress safely 
through proplatelet formation and platelet shedding.
©  2011  Josefsson  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first   
six  months  after  the  publication  date  (see  http://www.rupress.org/terms). 
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share  Alike  3.0  Unported  license,  as  described  at  http:// 
creativecommons.org/licenses/by-nc-sa/3.0/).
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overturn the notion that classical mitochondrial apoptosis is 
essential for platelet production. Instead, megakaryocytes must 
restrain apoptosis to survive and progress safely through pro-
platelet formation and platelet shedding. This striking finding 
has important implications for our understanding of human 
diseases where the apoptotic death of megakaryocytes has 
been implicated.
RESULTS
Platelet number and life span are increased in the absence 
of Bak and Bax
To determine the role of the intrinsic apoptosis pathway in 
platelet production, we generated mice with a constitutive 
deletion of Bak and a megakaryocyte-specific deletion of Bax. 
Bak/ animals were crossed with mice harboring a floxed 
allele of Bax (Baxfl; Takeuchi et al., 2005) and a Pf4-Cre trans-
gene from which Cre recombinase is expressed under the 
control of the Platelet factor 4 promoter (Tiedt et al., 2007). 
The latter mediates efficient deletion of floxed alleles from   
the earliest stages of megakaryocytic differentiation (Hitchcock   
et al., 2008; Pleines et al., 2010; Tiedt et al., 2007). At weaning, 
Bak/ BaxPf4/Pf4 mice were present in the expected Men-
delian ratios and were outwardly healthy and fertile. West-
ern  blot  analysis  of  platelet  and  megakaryocyte  lysates 
confirmed that Bak and Bax were efficiently deleted from 
the lineage (Fig. 1 a).
Consistent with the initial study (Mason et al., 2007), we 
found that peripheral blood platelet counts in Bak/ mice 
were significantly increased relative to wild-type counter-
parts (Fig. 1 b). Surprisingly, with the additional loss of Bax, 
platelet  numbers  remained  elevated.  Given  the  role  these 
two proteins play in the regulation of platelet life span, we 
examined the kinetics of platelet clearance in vivo. Deletion 
of Bax had a minor effect, with a modest but statistically sig-
nificant extension of platelet survival apparent (Fig. 1 c). In 
contrast, and as previously documented (Mason et al., 2007), 
platelet life span in Bak/ mice was almost doubled. This 
was also true of Bak/ Bax+/Pf4, and Bak/ BaxPf4/Pf4 
animals; in fact, platelet survival curves in Bak/, Bak/ 
Bax+/Pf4,  and  Bak/  BaxPf4/Pf4  were  indistinguishable. 
Transfusion of biotinylated platelets into wild-type recipi-
ents established that life span in all cases was independent of 
host genotype, i.e., cell intrinsic (Fig. S1 d). These data con-
firmed that at steady state, Bak is the critical factor limiting 
platelet life span. Concomitant loss of Bax does not further 
extend circulatory survival time. The results also suggested 
that platelet production does not require the intrinsic apop-
tosis pathway.
Megakaryopoiesis is normal in the absence of Bak and Bax
Given  the  platelet  data,  we  examined  the  megakaryocyte 
compartment  in  detail.  Megakaryocyte  numbers  in  the   
BM, as determined by histological (Fig. 1 d) and flow cyto-
metric analyses (unpublished data), were comparable across all 
genotypes.  Megakaryocyte  ploidy  (Fig.  1  e),  and  serum 
thrombopoietin (TPO) levels (Fig. 1 f) were unchanged in 
body of work supports this notion, most of it centered on   
the intrinsic (or mitochondrial) apoptosis pathway. Mice car-
rying mutations that impair apoptosis—by overexpression of 
prosurvival Bcl-2 (Ogilvy et al., 1999) or deletion of the   
proapoptotic  Bcl-2  family  member  Bim  (Bouillet  et  al., 
1999)—exhibit reduced circulating platelet counts (thrombo-
cytopenia). Overexpression of another close relative of pro-
survival Bcl-2, Bcl-xL, impairs proplatelet formation by cultured 
megakaryocytes (Kaluzhny et al., 2002). Similarly, pharma-
cological inhibition of caspases, the proteolytic enzymes re-
sponsible for dismantling dying cells, blocks the generation of 
proplatelets (De Botton et al., 2002; Clarke et al., 2003).
However, the precise requirement for apoptosis in platelet 
shedding has not been fully clarified. It is not understood 
how a megakaryocyte can undergo apoptosis and yet produce 
viable platelets that circulate in the bloodstream for days. Fur-
thermore, the idea that apoptosis is required for platelet pro-
duction is inconsistent with evidence that a range of insults, 
including chemotherapeutic agents, autoantibodies, and viruses, 
cause thrombocytopenia by inducing the apoptotic death of 
megakaryocytes and their progenitors (Ballem et al., 1987; 
Zucker-Franklin et al., 1989; Zauli et al., 1996; Chang et al., 
2003; Houwerzijl et al., 2004; McMillan and Nugent, 2005; 
Zeuner et al., 2007).
Given the postulated role of the intrinsic apoptosis path-
way in platelet production, we analyzed the consequences of 
blocking  or  activating  apoptosis  in  megakaryocytes,  using 
both genetic and pharmacological approaches. The intrinsic 
pathway to apoptosis is regulated by the Bcl-2 protein family 
(Youle and Strasser, 2008). The key mediators of this process 
are Bak and Bax, which if unrestrained, trigger mitochondrial 
outer membrane permeabilization (MOMP), an irreversible 
step toward apoptotic cell death (Green and Kroemer, 2004). 
Combined deficiency of Bak and Bax renders multiple cell 
types resistant to physiological and pathological inducers of 
apoptosis (Lindsten et al., 2000; Cheng et al., 2001). By selec-
tively deleting Bak and Bax within the megakaryocytic lin-
eage,  we  were  able  to  fully  evaluate  the  consequences  of 
blocking apoptosis on megakaryocyte biology both in vitro 
and in vivo. Much to our surprise, loss of Bak and Bax had no 
impact upon platelet production, even though platelet life 
span, as anticipated (Mason et al., 2007), was prolonged.
Normally, Bak and Bax are kept in check, either directly 
or indirectly, by the prosurvival Bcl-2 family members: Bcl-2 
itself, or close relatives such as Bcl-xL (Willis et al., 2007;   
Ren  et  al.,  2010). We  found  that  selectively  inactivating   
prosurvival  Bcl-xL  triggered  megakaryocyte  apoptosis  and 
failure of platelet production. Three agents that activate the in-
trinsic apoptosis pathway in other cell types, etoposide, stauro-
sporine (STS), and the BH3 mimetic ABT-737, all triggered 
mitochondrial damage, caspase activation and cell death in 
megakaryocytes in vitro. Deletion of Bak and Bax blocked 
the response to etoposide and ABT-737, but not STS. In vivo, 
loss of Bak and Bax rescued the defects caused by deletion   
of Bcl-xL, and ameliorated the thrombocytopenia caused   
by the chemotherapeutic agent carboplatin. Thus, our studies JEM Vol. 208, No. 10 
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exhibited  increased  survival,  persisting  with  proplatelets   
intact  for  several  days  longer  than  wild-type  counterparts   
(Fig. 2, a and b).
Bak- and Bax-mediated apoptosis is not required  
for platelet production
Collectively, our data indicated that there is no requirement 
for Bak- and Bax-mediated apoptosis in the production of 
platelets by megakaryocytes. To rule out the possibility that 
this is true only at steady state, we tested the ability of Bak/ 
BaxPf4/Pf4 mice to recover from acute thrombocytopenia in-
duced by antiplatelet serum (APS). 24 h after a single dose of 
APS, platelet counts had fallen to almost undetectable levels 
(Fig. 2 c). Subsequently, each genotypic class mounted a ro-
bust recovery of similar kinetics, with platelet counts exceed-
ing baseline by 6 d after APS (Fig. 2 c). Interestingly, visual 
inspection of BM sections taken from mice during the recov-
ery phase revealed an abundance of naked megakaryocyte 
nuclei (Fig. 2, d and e). This phenomenon was significantly 
increased in Bak/ BaxPf4/Pf4 mice relative to wild-type or 
Bak/ Baxfl/fl counterparts. Although less pronounced, the 
difference was also observed at steady state.
Given the surprising nature of our results, we elected to 
confirm them by generating chimeric animals in which the 
hematopoietic  system  was  reconstituted  with  constitutive 
knockout Bak/ Bax/ FLC (Fig. S1). These animals develop 
a complex disease characterized by an accumulation of lym-
phocytes in the peripheral blood, BM, and spleen (Rathmell   
et al., 2002; Fig. S1 e). In our hands, Bak/ Bax/ reconsti-
tuted mice developed splenomegaly, with spleens weighing 
2.5 times more than wild type at 8 wk after transplant (Fig. S1 f). 
Therefore, we splenectomized a group of wild-type C57BL/6 
CD45.1 recipients, and 4 wk later transplanted them with 
FLC. 8 wk after reconstitution, platelet counts and platelet life 
span in mice that had received Bak/ Bax/ FLC were   
the same as those seen in Bak/ and Bak/ Bax+/ animals 
(Fig. 2 f and Fig. S1, b and c). The response to APS-induced 
thrombocytopenia was normal (Fig. 2 f). These data demon-
strate that at both steady state and under conditions of throm-
bopoietic stress, the intrinsic mitochondrial apoptosis pathway 
is dispensable for platelet production.
Bcl-xL is required for platelet survival
Despite the fact that they express Bak and Bax, and a range of 
other apoptotic regulators (Krajewski et al., 1994; Sanz et al., 
2001; Fig. S2 i), our results raised the question of whether 
megakaryocytes possess a functional intrinsic apoptosis path-
way at all. If megakaryocytes are susceptible to activation of 
the intrinsic pathway to apoptosis, then one would expect 
that one or more members of the Bcl-2 family of prosurvival 
proteins must keep Bak and Bax in check to maintain cellular 
integrity. Given the known role of one such prosurvival, Bcl-xL, 
in regulating platelet life span (Mason et al., 2007), and given 
its documented expression in megakaryocytes (Terui et al., 
1998; Sanz et al., 2001; Kozuma et al., 2007), we generated a 
megakaryocyte-specific deletion of Bcl-x. Mice harboring a 
Bak/ BaxPf4/Pf4 mice. Semisolid agar cultures of BM cells 
(BMCs) and splenocytes demonstrated that committed my-
eloid (Bak+/+ Bax+/+, 87.5 ± 15.2; Bak/ BaxPf4/Pf4, 70.3 ± 
7.3) and megakaryocyte progenitor numbers (Bak+/+ Bax+/+ 
21.3 ± 7.1, Bak/ BaxPf4/Pf4 16.3 ± 0.5) were normal. 
Next, we derived mature megakaryocytes from the BM of 
adult Bak/ BaxPf4/Pf4 mice and assessed their ability to 
form proplatelets. To circumvent any potential issues relating 
to the timing of Pf4-Cre-mediated excision of Bax, mega-
karyocytes were also derived from fetal liver cells (FLC) har-
vested from constitutive Bak/ Bax/ knockout animals 
(Fig. 2 a). No decrease in the rate of proplatelet formation was 
observed in either case (Fig. 2 a and not depicted). Interestingly, 
proplatelet-bearing Bak- and Bax-deficient megakaryocytes 
Figure 1.  Thrombocytosis in the absence of Bak and Bax. (a) West-
ern blot of Bak/ BaxPf4/Pf4 cell lysates demonstrating efficient deletion 
of Bak and Bax in platelets, and cultured megakaryocytes (MGKs) derived 
from murine BM. Actin served as a control for protein loading. (b) Platelet 
counts in Bak/ Baxfl/fl, Bak/ BaxPf4/Pf4, Bak+/+Bax/, and control 
mice at 7 wk of age. Data represent mean ± SEM. Each symbol represents 
an individual mouse. (c) Platelet survival curves in Bak/ Baxfl/fl, Bak/ 
BaxPf4/Pf4, and Bak+/+Bax/ mice. Platelets were labeled via intravenous 
injection of a DyLight 488–conjugated anti-GPIb (CD42c) antibody. Data 
represent mean ± SD. n = 4–6 mice per group. (d) Morphologically recog-
nizable MGKs in H&E-stained sections of BM from Bak/Baxfl/fl, Bak/ 
BaxPf4/Pf4, Bak+/+ Bax/, and control mice. Each symbol represents the 
mean number per field of view (200×) from 8–10 fields per individual 
mouse. Data represent overall mean ± SEM. (e) MGK ploidy distribution 
profiles in adult conditional knockout mice. Data represent mean ± SD.  
n = 8 mice per genotype. (f) Serum thrombopoietin levels in adult condi-
tional knockout mice. Each symbol represents an individual mouse. Data 
represent mean ± SD. **, P < 0.005; ***, P < 0.0001.2020 Role of mitochondrial apoptosis in megakaryocytes | Josefsson et al.
was dramatically reduced to 5 h, versus 5 d for wild-type 
and Bcl-xfl/fl littermates (Fig. 3 c). A very small number of 
platelets survived in the circulation up to 24 h after labeling 
(Fig. S2, c and d), potentially the product of megakaryocytes 
in which Bcl-x had not been completely excised by the Cre 
enzyme. Collectively, the data confirm that Bcl-xL is abso-
lutely required for platelet survival in vivo.
Bcl-xL is required for normal platelet shedding
The abnormal morphology and cell surface phenotype of 
Bcl-xPf4/Pf4 platelets suggested that platelet production had 
been perturbed by the loss of the Bcl-xL in megakaryocytes. 
Mathematical modeling of production rates further supported 
the notion that the reduction in platelet life span could not 
explain the severity of thrombocytopenia (Fig. 3 d). Relative 
to Bcl-xfl/fl littermates, megakaryocyte numbers were signifi-
cantly increased in both the BM and spleen of Bcl-xPf4/Pf4 
mice (Fig. 3 e, Fig. S2 e, and not depicted). Megakaryocyte 
ploidy was skewed toward 32N (Fig. 3 f). Megakaryocyte pro-
genitor numbers were somewhat increased in Bcl-xPf4/Pf4 
mice (Fig. 3 g), and serum TPO levels were significantly re-
duced (Fig. 3 h). Collectively, these data were reminiscent of 
floxed allele (Rucker et al., 2000) were crossed with the trans-
genic Pf4-Cre strain to produce Bcl-xPf4/Pf4 animals. The 
latter were present at weaning at 80% expected numbers 
and  appeared  outwardly  healthy.  They  were  profoundly 
thrombocytopenic, with platelet counts of 2% those ob-
served in Bcl-xfl/fl mice (Fig. 3 a and Fig. S2 a). Mature cells of 
other hematopoietic lineages were unaffected (Table I).
Bcl-xPf4/Pf4 platelets were highly abnormal: mean platelet 
volume (MPV) was doubled and platelet distribution width 
(PDW) was significantly elevated relative to Bcl-xfl/fl in pe-
ripheral whole blood (Table I). There was also an abundance 
of microparticles in platelet-rich plasma (PRP) as determined 
by flow cytometric forward and side scatter profiling, and in-
creased phosphatidylserine (PS) exposure (Fig. 3 b and Fig. S2 
b). Only 20–30% of the cells present in PRP expressed the 
platelet-specific receptors CD41, GPIX, GPIb, or GPVI, 
compared with >95% in Bcl-xfl/fl (Fig. S2 b). To investigate 
circulating platelet life span, we intravenously injected mice 
with a fluorescently labeled platelet-specific anti-GPIb anti-
body derivative. 15 min after treatment, 95% of platelets 
were labeled in wild-type mice, but only 20% in Bcl-xPf4/Pf4 
littermates. The life span of the vast majority of labeled platelets 
Figure 2.  Bak and Bax are dispensable for platelet pro-
duction. (a) Proplatelet formation by large, mature fetal liver–
derived MGKs in culture. Data represent mean ± SEM. MGKs 
were pooled from two animals per genotype. n = 2 technical 
replicates. Representative of three independent experiments.  
(b) Representative images of wild-type and Bak/ Bax/ MGKs  
on day 6 and 8 of culture. On day 8, wild-type cultures con-
tained mostly cell debris; in contrast, Bak/ Bax/ wells con-
tained elaborate proplatelet formations. Bars, 50 µm. (c) Platelet 
counts in response to anti-platelet serum (APS)–induced throm-
bocytopenia in mice lacking Bak and Bax. Data represent mean 
± SEM. n = 8–11 mice at 120 h (except Bak+/+Bax/, n = 3);  
n = 5–6 at 144 h; and n = 3–6 at 192 h per genotype, per time 
point. (d, left) Morphologically recognizable MGKs before and 
after APS in H&E-stained sections of BM from mice lacking Bak 
and Bax. Mean number per field of view (200×) from 10 fields 
per individual mouse. Data represent overall mean ± SD. n = 4–14   
untreated mice per group; n = 5–6 at 96 h; n = 12–15 at 120 h; 
and n = 3 at 144 h. (middle and right) Naked MGK nuclei in 
H&E-stained sections of BM from mice lacking Bak and Bax, at 
steady state, and in response to APS-induced thrombocytopenia 
(taken 96, 120, and 144 h after injection). (d, middle) Data repre-
sent mean number per field of view (200×) from 6 fields per 
individual mouse ± SEM. n = 4–15 untreated mice per group;  
n = 5–6 at 96 h; n = 12–17 mice per group at 120 h; and n = 3 
at 144 h. (d, right) Fold change in naked nuclei. Number of  
nuclei post-APS divided by mean number in corresponding 
untreated group (0 h). (e) Representative images of H&E-stained 
sections of BM from wild-type and Bak/ BaxPf4/Pf4 mice,  
120 h after injection of APS. Arrows indicate naked nuclei. Bars, 
20 µm. (f) Platelet counts in response to APS-induced thrombo-
cytopenia. Lethally irradiated mice were reconstituted with FLCs 
lacking Bak and Bax and injected with APS 8 wk after transplan-
tation. A group of recipients was splenectomized 3–4 wk before 
reconstitution. Data represent mean ± SEM. n = 7–10 mice per 
group at 120 h; n = 3–5 mice per group at 96 and 144 h.  
*, P < 0.05; **, P < 0.005; ***, P < 0.0001.JEM Vol. 208, No. 10 
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performed (Fig. 4 c and Videos 1 and 2). Bcl-xfl/fl megakaryo-
cytes sent out long extensions and formed elaborate pro-
platelets. In contrast, Bcl-xPf4/Pf4 megakaryocytes generated 
extensions, but they were significantly fewer, much shorter, 
and less detailed. Bcl-xPf4/Pf4 megakaryocytes died soon after 
they had formed these short extensions. To visualize phospha-
tidylserine exposure, Alexa Fluor 488–conjugated Annexin   
V was included in the media (Fig. 4 d and  Videos 3 and 4). Mini-
mal PS was observed on Bcl-x+/+ megakaryocytes as they pro-
ceeded through proplatelet formation. However, several hours 
after the process appeared to be complete, proplatelet-bearing 
megakaryocytes were seen to collapse in on themselves and 
stain intensely positive for Annexin. Bcl-xPf4/Pf4 megakaryo-
cytes on the other hand, did not form proplatelets, and al-
though they were not Annexin+ at the beginning of culture, they 
exposed increasing levels of PS as they subsequently died.
Collectively, our data suggested that megakaryocytes be-
come dependent on Bcl-xL just as they reach the point of 
proplatelet formation and platelet shedding. In the absence of 
Bcl-xL, mature megakaryocytes are unable to undergo normal 
shedding and die an apoptotic death. We looked for evidence 
of this process in vivo via transmission electron microscopy of 
those  from  mice  lacking  the  transcription  factor  NF-E2, 
which although able to generate mature megakaryocytes, suf-
fer a profound defect in platelet shedding and severe throm-
bocytopenia (Shivdasani et al., 1995; Lecine et al., 1998; Levin 
et al., 1999).
To elucidate the consequences of Bcl-x deletion on mega-
karyocyte development, we cultured Bcl-xfl/fl and Bcl-xPf4/Pf4 
FLC in serum-free media with TPO. To control for any variabil-
ity in the deletion of the floxed allele of Bcl-x, FLC from mice 
homozygous for a constitutive knockout allele, denoted Bcl-x/ 
(Motoyama  et  al.,  1995),  were  cultured  in  parallel.  Bcl-x+/+,   
Bcl-xfl/fl, Bcl-xPf4/Pf4, and Bcl-x/ FLC cultures produced simi-
lar numbers of megakaryocytes (Fig. 3 i). This agreed with our in 
vivo data, confirming that Bcl-xL is not required for the develop-
ment and growth of megakaryocytes. We next assessed the ability 
of mature megakaryocytes to generate proplatelets. In striking 
contrast to gradient-purified Bcl-x+/+ and Bcl-xfl/fl megakaryo-
cytes, Bcl-x/ and Bcl-xPf4/Pf4 cells exhibited an almost total 
failure of proplatelet formation (Fig. 4, a and b). This was accom-
panied by a rapid loss of viability.
To investigate these phenomena more closely, time-lapse 
video microscopy of mature megakaryocytes in culture was 
Figure 3.  Bcl-xL is essential for platelet survival.  
(a) Platelet counts at 7 wk of age in mice with a  
Pf4-Cre–mediated deletion of Bcl-x. Each symbol repre-
sents an individual mouse. Data represent mean ± SEM.  
n = 15–23 mice per genotype. (b) Representative flow 
cytometric forward and side scatter profiles of CD41+ve 
platelets in PRP derived from wild-type and Bcl-xPf4/Pf4 
mice. (c) In vivo survival of CD42c+ve platelets in Bcl-xPf4/Pf4 
mice. Platelets were labeled via intravenous injection  
of a DyLight 488–conjugated anti-GPIb (CD42c) anti-
body. Blood samples were collected 0.25, 1, 3, and 5 h 
after labeling. Data represent mean ± SEM. n = 8 mice 
for Bcl-xPf4/Pf4; n = 4 for wild type; n = 3 for Bcl-xfl/fl;  
n = and 2 for Bcl-x+/fl, Bcl-x+/Pf4. P < 0.0001 at 5 h.  
(d) Calculated platelet production rates in wild-type and  
Bcl-xPf4/Pf4 mice as described in Materials and methods. 
P < 0.0001, two-tailed unpaired Student’s t test. (e) Mor-
phologically recognizable MGKs in H&E-stained sections 
of BM from Bcl-xPf4/Pf4 mice. Each symbol represents 
mean number per field of view (200×) from five fields per 
mouse. Data represent overall mean ± SEM. (f) Ploidy 
distribution profile of CD41+ve BMCs. Data represent 
mean ± SEM. n = 6 mice per genotype. (g) Hematopoietic 
progenitor cell numbers in adult mice. 25,000 BMCs were 
cultured with stem cell factor, IL-3, and erythropoietin in 
semisolid agar for 7 d. Non-MGK colonies represent the 
total of blast, granulocyte, mixed granulocyte/macrophage, 
macrophage, and eosinophil colonies. Data represent 
mean ± SEM. n = 7–11 mice per genotype. **, P = 0.0021. 
(h) Serum TPO levels. Each symbol represents an indi-
vidual mouse. Data represent mean ± SEM. ***, P < 0.0001.  
(i) MGK differentiation from mouse FLC. E12.5 Bcl-x+/+ 
and Bcl-x/, and E13.5 Bcl-xfl/fl, and Bcl-xPf4/Pf4 fetal 
livers were cultured in TPO for 3–5 d and the develop-
ment of CD41+ve cells measured by flow cytometry. Data 
represent mean ± SD. n = 3–5 biological replicates  
(except day 3, n = 2). **, P < 0.005; ***, P < 0.0001.2022 Role of mitochondrial apoptosis in megakaryocytes | Josefsson et al.
shed were seen in the circulation; they appeared to be highly 
vacuolated and morphologically abnormal (Fig. 5 a, bottom 
right; and Fig. S3). These observations were consistent with 
late-stage megakaryocyte death, but did not absolutely prove 
an intrinsic physiological dependence upon Bcl-xL, given the 
associated dramatic reduction in platelet life span and platelet 
number exhibited by Bcl-xPf4/Pf4 mice.
To establish whether megakaryo-
cytes  lacking  Bcl-xL  could  produce 
platelets normally in the absence of se-
vere thrombocytopenic stress, we gen-
erated BM chimeras by transplanting 
50:50 ratios of Bcl-x+/+ or Bcl-x Pf4/Pf4 
BMCs with wild-type GFP-expressing 
Bcl-xfl/fl  and  Bcl-xPf4/Pf4  BM  sections. As  expected,  many 
megakaryocytes  displaying  normal  ultrastructure  were  ob-
served in the knockout (Fig. 5 a, bottom left). However, strik-
ingly abnormal cells, projecting large vacuolated fragments of 
cytoplasm into the sinusoidal spaces were also evident (Fig. 5 a, 
bottom middle; and Fig. S3). Discrete fragments that had been 
Table I.  Blood counts in mice lacking Bcl-xL in the megakaryocyte lineage
Bcl-x fl/fl Bcl-x +/fl Bcl-x +/Pf4 Bcl-x Pf4/Pf4
n = 12 n = 16 n = 20 n = 20
Platelets (×106/ml) 1,139 ± 150 1,163 ± 170 697 ± 100b 22 ± 4b
aPlatelets (×106/ml) 939 ± 92 52 ± 28b
MPV (femtoliters) 7.7 ± 0.6 7.1 ± 0.9 7.3 ± 0.8 14.0 ± 2.5b
PDW (%) 53.2 ± 4.2 51.2 ± 5.6 52.3 ± 7.1 78.9 ± 20.9b
Erythrocytes (×109/ml) 10.7 ± 0.4 10.7 ± 0.5 10.7 ± 0.5 10.1 ± 0.6
Hematocrit (%) 50.8 ± 1.7 51.1 ± 2.2 51.4 ± 2.3 49.1 ± 2.2
Leukocytes (×106/ml) 10.5 ± 1.7 9.4 ± 2.0 10.2 ± 2.4 9.1 ± 1.8
Neutrophils (×106/ml) 0.8 ± 0.2 0.8 ± 0.1 0.9 ± 0.2 0.8 ± 0.2
Lymphocytes (×106/ml) 9.1 ± 1.5 8.0 ± 1.8 8.8 ± 2.3 7.6 ± 1.6
Monocytes (×106/ml) 0.2 ± 0.1 0.2 ± 0.0 0.2 ± 0.1 0.3 ± 0.1
Eosinophils (×106/ml) 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.1
Peripheral blood cell counts from mice at 7 wk of age. MPV, mean platelet volume; PDW, platelet distribution width. Data represent mean ± SD.
aPlatelet counts in whole blood determined by flow cytometry with Sphero blank calibration particles (3.5–4.0 µm), gating on CD41+ve and TER-119-ve cells. n = 3 mice per 
genotype. Unpaired Student’s t test with two-tailed p-values.
bP < 0.001, with respect to control mice Bcl-xfl/fl or Bcl-x+/fl, 1 way ANOVA with Bonferroni’s multiple comparison correction.
Figure 4.  Megakaryocytes require Bcl-xL 
for survival during platelet formation. 
Proplatelet formation (a) and viability (b) of 
cultured fetal liver–derived MGKs harboring a  
constitutive or conditional deletion of Bcl-x. 
Data represent mean ± SEM. Bcl-x+/+, n = 7; 
Bcl-x/, n = 8; Bcl-xfl/fl, n = 18; and Bcl-xPf4/Pf4,  
n = 13 technical replicates. n = 3 biological 
replicates for Bcl-x/; n = 5 for Bcl-xPf4/Pf4  
and corresponding controls. (c) Representative 
still images from time-lapse video microscopy 
of cultured fetal liver-derived Bcl-xfl/fl (Video 1) 
and Bcl-xPf4/Pf4 (Video 2) MGKs. Frames were 
captured every minute for 24 h. Videos run at 
25 frames/s. Videos start at 10.7 h (Video 1) 
and 1.3 h (Video 2). Time (h). Bar, 100 µm.  
(d) Representative still images from time-lapse 
video microscopy of cultured fetal liver–derived 
Bcl-x-+/+ (Video 3) and Bcl-xPf4/Pf4 (Video 4) 
MGKs binding Alexa Fluor 488–conjugated  
Annexin V (green). Frames were captured  
every 15 min for 24 h. Videos run at 6 frames/s. 
Time (h). Bar, 100 µm.JEM Vol. 208, No. 10 
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in caspase activity and a concomitant reduction in ATP levels 
were observed (Fig. 6, c and d). ABT-737 inhibited proplate-
let formation in a dose-dependent manner (Fig. 6 e). Col-
lectively,  these  data  indicate  that  genetic  deficiency  or 
pharmacological inhibition of Bcl-xL triggers the intrinsic 
apoptosis pathway, leading to caspase activation and failure   
of proplatelet formation. We conclude that caspase activation 
has  a  negative  impact  on  the  ability  of  megakaryocytes   
to produce platelets. This runs counter to previous studies 
suggesting  that  megakaryocytes  require  apoptotic  caspases   
to facilitate platelet shedding (De Botton et al., 2002; Clarke 
et al., 2003).
We therefore examined the role of caspases in proplatelet 
formation more closely. Wild-type megakaryocytes were in-
cubated with two distinct broad-spectrum caspase inhibitors, 
z-VAD.fmk (Dolle et al., 1994) and Q-VD-OPh (Caserta   
et al., 2003). In agreement with previous studies, cells cultured 
with high doses of z-VAD.fmk exhibited a significant impair-
ment of proplatelet formation and loss of viability (Fig. 6,   
f  and  g).  In  contrast,  neither  effect  was  observed  with   
Q-VD-OPh (Fig. 6, f and g). In fact, proplatelets formed by 
megakaryocytes treated with Q-VD-OPh exhibited a similar 
increase in stability and survival to those formed by Bak/ 
Bax/ megakaryocytes (Fig. 2, a and b). Because Q-VD-
OPh did not impair proplatelet formation or viability, we 
tested whether it could ameliorate the effects of ABT-737 on 
wild-type megakaryocytes. Interestingly, although preincuba-
tion with Q-VD-OPh could hinder the loss of mitochondrial 
function triggered by ABT-737 (Fig. 7 a), it did not rescue 
proplatelet formation (unpublished data). Collectively, these 
data indicate that activation of the intrinsic apoptosis pathway 
induces mitochondrial damage and caspase activation, result-
ing in failure of platelet shedding and cell death.
Deletion of Bak and Bax protects 
megakaryocytes from apoptotic signals
Bak and Bax are the gatekeepers of the intrinsic 
apoptosis pathway in a wide range of cells, in-
cluding platelets. We therefore asked whether 
BMCs  into  lethally  irradiated  adult  recipients.  7  wk  after 
transplant,  recipients  of  Bcl-x+/+/GFP  BMCs  had  platelet 
counts of 959 ± 145, and recipients of Bcl-x Pf4/Pf4/GFP had 
platelet counts of 354 ± 69, an 16-fold increase relative to 
Bcl-x  Pf4/Pf4 mice (Fig. 5 b, left). As expected, given their 
short life span, <10% of platelets in recipients of Bcl-x Pf4/Pf4/
GFP BMC were GFP-ve (Fig. 5 b, middle). In both models, 
wild-type platelet morphology, whether GFP+ve or GFP-ve, 
was normal (Fig. 5 b, right). In contrast, Bcl-xPf4/Pf4 GFP-ve 
platelets displayed the same disturbed morphological profile 
as those from unmanipulated Bcl-xPf4/Pf4 mice (Fig. 5 b). 
Thus, even in the absence of the severe thrombocytopenic 
stress, megakaryocytes lacking Bcl-xL undergo an abnormal 
platelet shedding process. Collectively, these data demonstrate 
that megakaryocytes are dependent on Bcl-xL to maintain 
survival during platelet shedding.
Inhibition of Bcl-xL triggers megakaryocyte apoptosis
To more fully understand the death process in Bcl-xPf4/Pf4 
megakaryocytes, we measured apoptotic effector caspase ac-
tivity in mature, unmanipulated FLC-derived cells. Bcl-x/ 
and Bcl-xPf4/Pf4 megakaryocytes exhibited a fivefold increase 
in the activity of caspase-3/7 (Fig. 6 a) and -9 (not depicted) 
relative to Bcl-x+/+ and Bcl-xfl/fl counterparts. ATP levels, a 
marker  of  mitochondrial  function,  were  dramatically  de-
creased after 24 h of culture (Fig. 6 b). These results are con-
sistent with loss of Bcl-xL inducing the intrinsic apoptosis 
cascade. We then asked whether pharmacological inhibition 
of Bcl-xL could achieve the same effect. Wild-type FLC- and 
BM-derived  mature  megakaryocytes  were  incubated  with 
the small molecule ABT-737, a BH3 mimetic drug that an-
tagonizes Bcl-xL and the related prosurvival proteins Bcl-2 
and Bcl-w (Oltersdorf et al., 2005). After 5 h, a sixfold increase 
Figure 5.  Platelet production is abnormal in the 
absence of Bcl-xL. (a) Representative transmission elec-
tron microscope images of BM sections showing aber-
rant MGK morphology and abortive platelet shedding  
in Bcl-xPf4/Pf4 mice. Arrows indicate normal platelets in 
wild-type and large megakaryocyte-derived fragments in 
Bcl-xPf4/Pf4 animals. Red blood cell (R). Bars: 5 or 10 µm, 
as indicated. See Fig. S3 for higher magnification images. 
(b) Mice reconstituted with a 50:50 mixture of Bcl-xPf4/Pf4 
and wild-type GFP-expressing BMCs. (left) Platelet 
counts in peripheral blood 7 wk after transplant, mean ± 
SEM. (middle) Percent CD41+ve GFP+ve platelets; mean ± SD.  
n = 6. (right) Flow cytometric forward and side scatter 
plots of CD41+ve platelets in PRP. In these mice, GFP+ve 
platelets were produced by wild-type MGKs, GFP-ve plate-
lets by Bcl-xPf4/Pf4 MGKs. Plots are representative of  
n = 6 recipient mice per transplant group.2024 Role of mitochondrial apoptosis in megakaryocytes | Josefsson et al.
no effect. In contrast, Bak/Bax double deficiency completely 
rescued the defects in platelet production caused by loss of 
Bcl-xL (Fig. 7 d). This encouraged us to examine the role of 
Bak and Bax in chemotherapy-induced thrombocytopenia, 
specifically carboplatin, an agent with a well-described pro-
pensity to cause thrombocytopenia in patients (Budd et al., 
1999). Given that carboplatin, along with many other stan-
dard chemotherapeutics, is thought to kill both megakaryo-
cytes and their progenitors (Zeuner et al., 2007), we generated 
wild-type  and  Bak/  Bax/  FLC-reconstituted  animals.   
At 8 wk after transplantation, these were treated with a single 
dose of carboplatin. Loss of Bak and Bax significantly ame-
liorated both the thrombocytopenia (Fig. 7 e) and anemia   
(Fig. 7 f) triggered by the drug.
DISCUSSION
Our studies demonstrate that megakaryocytes possess an in-
trinsic apoptosis pathway, the key components of which are 
prosurvival Bcl-xL, and prodeath Bak and Bax. Contrary to 
the widely accepted model, this pathway is not activated by 
megakaryocytes  to  facilitate  platelet  shedding.  Deletion  of 
Bak and Bax, the gatekeepers of the intrinsic apoptosis path-
way, had no adverse effect on megakaryocyte number, ploidy, 
they mediate megakaryocyte death in response to proapop-
totic stimuli. Mature fetal liver- and BM-derived megakaryo-
cytes were exposed to three compounds that are known to 
induce the intrinsic apoptosis pathway in other cell types: 
ABT-737, the topoisomerase II inhibitor etoposide, and the 
broad-spectrum kinase inhibitor STS. In wild-type cells, all three 
compounds induced a dramatic reduction in ATP levels (Fig. 7 a 
and Fig. S4) and a concomitant increase in apoptotic caspase 
activity (Fig. 7 b). This was accompanied by failure of pro-
platelet formation (Fig. 7 c). Strikingly, in the case of ABT-737, 
genetic deletion of Bak and Bax could completely rescue 
megakaryocytes from these effects. Viability, caspase activity, 
and proplatelet formation were all normal in Bak/ Bax/ 
megakaryocytes treated with the drug (Fig. 7, a–c; and Fig. S4). 
Interestingly, Bak/ Bax/ megakaryocytes were protected 
from etoposide also, but still exhibited an impairment of pro-
platelet formation (Fig. 7, a–c). This was in contrast to the   
effects of STS, which were in no way ameliorated by loss of the 
prodeath proteins (Fig. 7, a–c).
To examine whether loss of Bak and Bax could protect 
the megakaryocyte lineage in vivo, we first deleted Bak and 
Bax in Bcl-xPf4/Pf4 mice. In agreement with Kodama et al. 
(2011), we found that single deficiency of either protein had 
Figure 6.  Genetic or pharmacological inhibi-
tion of Bcl-xL causes megakaryocyte apopto-
sis. (a) Caspase-3/7 activity in FLC-derived MGKs. 
Fetal livers were cultured in serum free media 
plus TPO for 3 d. Large MGKs were purified from a 
BSA-gradient and reseeded. 5 h later, caspase 
activity was measured using the Caspase-Glo 
assay system. Data represent fold increase com-
pared with control ± SEM. n = 2 biological repli-
cates for each genotype. (b) Viability of MGKs 
derived from fetal liver was measured 24 h after 
reseeding using the CellTiter-Glo assay system. 
Data represent mean ± SD. n = 3 independent 
experiments. Control was set as 100%.  
(c and d) MGKs derived as in a from fetal liver (FL) 
or BM (BM) were treated with ABT-737 (5 µM) or 
vehicle (DMSO) in serum-free media plus TPO.  
(c) Caspase-3/7 activity was measured after 5 h. 
Data represent fold increase compared with 
DMSO control. n = 6 independent experiments for 
FL; n = 3 for BM. (d)  Viability after 24 h. n = 4 
independent experiments. DMSO control was set 
as 100%. MGK were pooled from animals of same 
genotype. Mean ± SEM (e) Proplatelet formation 
by wild-type fetal liver–derived MGKs treated 
with ABT-737 or vehicle (DMSO). Data represent 
mean ± SEM. n = 6 technical replicates (except 5 µM, 
n = 2). Representative of three independent ex-
periments. (f) Proplatelet formation by wild-type, 
FLC-derived MGKs treated with caspase inhibitors 
z-VAD.fmk or Q-VD-OPh or vehicle (DMSO). Data 
represent mean ± SEM, n = 2 technical replicates. Representative of three independent experiments. (g) Viability of MGKs incubated with z-VAD.fmk,  
Q-VD-OPh, or vehicle (DMSO). Cells were derived as in a from fetal liver and reseeded with the relevant agent. Viability was measured 24 h after reseeding 
using the CellTiter-Glo assay system. Untreated control was set as 100%. Data represent mean ± SD. n = 2 technical replicates in two independent experi-
ments. *, P < 0.05; **, P < 0.005; ***, P < 0.0001.JEM Vol. 208, No. 10 
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activation, and death. 
A similar phenom-
enon was observed 
in mature, unmanip-
ulated  megakaryo-
cytes lacking Bcl-xL. 
In both cases, proplatelet formation failed. Genetic deletion 
of Bak and Bax could block death and rescue proplatelet for-
mation in the presence of ABT-737, and completely restored 
platelet production in mice lacking Bcl-xL. Thus, megakaryo-
cytes require Bcl-xL to restrain the activity of Bak and Bax 
during platelet production.
Our data indicate that megakaryocytes become depen-
dent on Bcl-xL just as they enter into proplatelet formation. It 
is not required for their growth and development, as indicated 
by the abundance of polyploid megakaryocytes in the BM of 
Bcl-xPf4/Pf4 mice, and in the yield of large mature cells from 
cultures of Bcl-xL–deficient BM and fetal liver. Unlike their 
wild-type counterparts, however, cultured Bcl-xPf4/Pf4 mega-
karyocytes are unable to elaborate proplatelets, instead under-
going Bak/Bax-dependent death which is accompanied by 
significant exposure of PS. Although the situation in vivo is 
or proplatelet formation. Platelet production at steady state, or 
in  response  to  experimentally  induced  thrombocytopenia, 
was normal. This was true whether Bak and Bax were condi-
tionally or constitutively deleted from the megakaryocyte lin-
eage. The only abnormality we observed was an increase in 
the number of naked megakaryocyte nuclei when both Bak 
and Bax were deleted. Although apparent at steady state, the 
phenomenon was much more pronounced during recovery 
from thrombocytopenia. This suggests that Bak and Bax me-
diate the clearance of the megakaryocyte nucleus after plate-
let shedding. Whether or not this is an apoptotic process is 
unclear. It is certainly possible; we observed a thin ring of cyto-
plasm around naked nuclei, perhaps this is normally the site of 
postshedding apoptosis designed to ensure swift engulfment. 
In support of this notion, our live cell imaging data demon-
strated that, in vitro, wild-type megakaryocytes expose significant 
levels of PS once proplatelet formation is complete.
In stark contrast to their absence, the activation of Bak 
and Bax had a profound and detrimental impact on mega-
karyocytes. Wild-type cells treated in vitro with the proapop-
totic agent ABT-737, which inhibits Bcl-xL, Bcl-2, and Bcl-w 
(Oltersdorf et al., 2005), suffered mitochondrial damage, caspase 
Figure 7.  Deletion of Bak and Bax pro-
tects megakaryocytes from death signals. 
(a) Viability of Bak- and Bax-deficient MGKs 
in response to ABT-737, etoposide, and STS. 
Mature FLC-derived MGKs were purified from 
a BSA gradient and cultured in serum-free 
media with TPO and either ABT-737 (5 µM), 
Etoposide (50 µM), STS (10 µM), vehicle con-
trols DMSO (0.05% ABT-737, 1%, STS), or 
ethanol (EtOH) 0.27%, or in combination with 
Q-VD-Oph (50 µM). Viability was measured 24 h 
after reseeding using the CellTiter-Glo assay 
system. DMSO control–treated Bak/Bax/ 
levels were set as 100%. Data represent mean ± 
SEM. n = 3–4 independent experiments.  
(b) Caspase-3/7 activity in MGKs derived and 
treated as in a. Caspase-Glo assay was con-
ducted 5 h after reseeding. MGK were pooled 
from >4 animals per genotype. Data represent 
mean ± SEM. n = 4 independent experiments. 
(c) Proplatelet formation in MGKs derived and 
treated as in a. Data represent mean ± SD,  
n = 2 technical replicates. MGKs were pooled 
from >2 animals per genotype. Representative 
of two independent experiments. (d) Platelet 
counts at 7 wk of age in mice lacking Bcl-xL, 
Bak, and Bax in the MGK lineage. Each symbol 
represents 1 mouse. Data represent mean ± 
SEM. n = 6–10 mice per genotype. (e) Platelet 
counts in lethally irradiated mice reconsti-
tuted with FLC, and injected with a single IP 
injection of carboplatin (100 mg/kg) on day 0. 
Cohorts of mice (day 8; n = 13 Bak+/+Bax+/+ and 
17 Bak/Bax/; day 11, n = 21 Bak+/+Bax+/+ 
and 24 Bak/Bax/; day 16, n = 13 Bak+/+Bax+/+ 
and n = 16 Bak/Bax/) were sacrificed at 
indicated time points. Data represent mean 
percentage of change to baseline ± SEM.  
(f) Erythrocyte counts from the experiment pre-
sented in e. Data represent mean percentage 
of change from baseline ± SEM. *, P < 0.05;  
**, P < 0.005; ***, P < 0.0001.2026 Role of mitochondrial apoptosis in megakaryocytes | Josefsson et al.
lacking Bak and Bax exhibited a similar increase in stability 
and survival, we believe the most likely explanation for the 
discrepancy between the two inhibitors is that high doses of 
z-VAD.fmk  trigger  caspase-independent  toxicity  in  mega-
karyocytes. It is known that z-VAD.fmk has potent activity 
against cathepsins B, H, and L (Chauvier et al., 2007), and in 
some cells can lead to necrosis (Temkin et al., 2006; Wu et al., 
2011). In fact, in 2009 the Nomenclature Committee on Cell 
Death recommended that the term z-VAD.fmk-inhibitable 
should be used in preference to “caspase-dependent” (Kroemer 
et al., 2009).
In addition to the intrinsic apoptosis pathway, the extrin-
sic pathway has also been implicated in platelet shedding. 
Treatment of MEG-01 cells with Fas ligand (FasL) or an anti-
Fas agonistic antibody was reported to increase proplatelet 
formation and production of platelet-like particles (Clarke   
et  al.,  2003).  Similar  results  were  obtained  with  primary 
mouse megakaryocytes or human bone core explants subjected 
to Fas agonism. This might suggest that although the intrinsic 
pathway is dispensable for platelet shedding, either the extrin-
sic pathway alone is required, or a combination of both is es-
sential. Our results with Q-VD-OPh argue against this notion, 
as Fas signaling is mediated by caspase-8 (Boldin et al., 1996; 
Fernandes-Alnemri  et  al.,  1996;  Muzio  et  al.,  1996)  and   
Q-VD-OPh is an effective inhibitor of this critical initiator 
(Chauvier et al., 2007). Genetic deletion studies will be re-
quired to define the role of the extrinsic apoptosis pathway in 
megakaryocyte biology.
Our results with carboplatin demonstrate that deletion of 
Bak  and  Bax  can  significantly  protect  the  megakaryocyte   
lineage against a pathophysiological insult in vivo. Chemother-
apy-induced thrombocytopenia (CIT) remains a significant 
unmet clinical need (Vadhan-Raj, 2009), and it will be inter-
esting to see whether Bak/Bax-mediated killing contributes 
to CIT caused by other agents. In addition to cytotoxic drugs, 
it is conceivable the pathway might also be activated by auto-
antibodies, viral infections such as HIV, or radiation. In sup-
port  of  the  latter  notion,  ablation  of  Bak  and  Bax  in 
hematopoietic and endothelial cells was recently shown to 
protect the BM and increase the survival of mice exposed to 
12.5  Gy  of  whole-body  irradiation  (Kirsch  et  al.,  2010). 
Whether loss of Bak and Bax can specifically protect the mega-
karyocyte lineage against radiation remains to be established.
Because carboplatin causes the death not just of mega-
karyocytes, but of megakaryoblasts and megakaryocyte pro-
genitors (Zeuner et al., 2007), the protection conferred by 
loss of Bak and Bax suggests that the intrinsic pathway must 
be restrained throughout the developing megakaryocyte lin-
eage. Prosurvival proteins expressed in megakaryocytes in-
clude Bcl-xL, Bcl-2, and Mcl-1 (Sanz et al., 2001; Zeuner et al., 
2007; this study). One explanation for the fact that loss of Bcl-xL 
only appears to affect megakaryocytes undergoing platelet 
shedding might be that it is the sole prosurvival protein ex-
pressed at this critical juncture. The heterogeneous nature of 
megakaryocyte cultures makes this a difficult notion to test, and 
the fact that platelets express Bcl-2 suggests otherwise. Perhaps a 
more difficult to visualize, there is no doubt that platelet pro-
duction is disturbed, independently of the severe thrombocy-
topenia that results from loss of Bcl-xL in platelets. This is 
demonstrated by the ultrastructural analysis, and also the BM 
chimera experiments which confirmed that even in the pres-
ence of wild-type hematopoiesis, Bcl-xPf4/Pf4 megakaryo-
cytes produce morphologically aberrant platelets.
Clearly, induction of Bak- and Bax-mediated apoptosis 
results in a failure of platelet shedding, but it appears there are 
additional  mechanisms  by  which  proapoptotic  stimuli  can 
block proplatelet formation. Although Bak- and Bax-deficient 
megakaryocytes were resistant to etoposide-induced mito-
chondrial damage and caspase activation, they still exhibited a 
failure of proplatelet formation. This suggests that DNA dam-
age may suppress platelet shedding independently of apopto-
sis occurring. Etoposide treatment results in DNA double-strand 
and single-strand breaks (Wozniak and Ross, 1983), which 
trigger activation of kinase signaling cascades, primarily the 
ATM–Chk2 and ATR–Chk1 pathways (Cimprich and Cortez, 
2008). The role of these pathways in megakaryocytes, and the 
mechanism by which they might influence proplatelet for-
mation is yet to be established. Interestingly, even in the ab-
sence of Bak and Bax, STS, a classical inducer of the intrinsic 
apoptosis pathway, was able to induce mitochondrial damage 
and caspase activation in megakaryocytes. This contrasts with 
Bak/ Bax/ mouse embryonic fibroblasts, which are resis-
tant (Wei et al., 2001). These data indicate that megakaryo-
cytes possess additional cell death signaling pathways, and, as 
Q-VD-OPh  could  not  block  STS-induced  mitochondrial 
damage, they are likely to be caspase independent.
Our findings contradict a substantial body of literature 
which holds that megakaryocytes deliberately use the apop-
totic machinery to facilitate platelet production. We believe 
that many of the apparent discrepancies can be explained. 
First, several of the key studies reporting that impaired apop-
totic signaling diminishes platelet production involved over-
expression of Bcl-2 family survival proteins, either in mice or 
in cell culture (Ogilvy et al., 1999; De Botton et al., 2002; 
Kaluzhny et al., 2002). Overexpression of any protein can im-
pact on cellular processes in complex and unforeseen ways, 
and Bcl-2 has been linked to the cell cycle (Vairo et al., 1996), 
calcium homeostasis (Bassik et al., 2004), autophagy (Pattingre   
et al., 2005), and inflammasome function (Bruey et al., 2007). 
Indeed, it has recently been demonstrated that Bcl-2 trans-
genic mice, which exhibit thrombocytopenia (Ogilvy et al., 
1999),  recover  normal  platelet  counts  upon  splenectomy   
(Kozuma et al., 2009). Second, data from in vitro culture sys-
tems, cell lines, and chemical inhibitor studies should be inter-
preted with caution. Our results agree with previous studies 
that high concentrations of the caspase inhibitor zVAD.fmk 
can inhibit proplatelet formation by megakaryocytes (De Botton 
et al., 2002; Clarke et al., 2003). In contrast, however, we 
found  that  the  difluorophenoxy-methylketone-based  pan-
caspase inhibitor Q-VD-OPh does not. Wild-type proplate-
lets in cultures treated with Q-VD-OPh survived significantly 
longer than untreated counterparts. Given that proplatelets JEM Vol. 208, No. 10 
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harvested from murine bones and flushed into DME Kelso, 10% FCS. Red 
cells were lysed, and the nucleated cells were counted. The cells were lineage 
depleted by incubation with a mix of antibodies (CD4, CD2, CD3, CD5, 
CD8, CD11b, erythroid, CD19, Gr-1, B220/CD45R; WEHI) in KDS BSS 
2% FCS, followed by goat anti–rat IgG magnetic beads (Bio Mag; QIAGEN). 
5 × 105 cells/ml were seeded in 6-well plates into serum-free media (SFM; 
Norol et al., 1998) supplemented with 100 ng/ml murine TPO (WEHI). 
Cells were cultured for 3–5 d at 37°C, 5% CO2. To isolate dense, viable,   
mature megakaryocytes, cells were overlaid on a discontinuous BSA (BSA 
Fraction  V; Invitrogen) density gradient (3, 1.5, and 0%; Drachman et al., 1997), 
and cells were harvested in the 3% layer.
Proplatelet formation assay. Large fetal liver or BM derived megakaryo-
cytes were seeded in 96-well plates 300–500 cells/well into SFM supple-
mented with TPO. Cells were cultured with or without the addition of 
ABT-737 (5 µM), etoposide (50 µM), STS (10 µM), Q-VD-OPh (50 µM), 
vehicle controls DMSO, and ethanol if not otherwise stated. Megakaryocytes 
displaying proplatelets were counted by microscopy and percentage was cal-
culated by dividing the number of proplatelet forming megakaryocytes with 
the total number of cells each day. Percentage of live megakaryocytes in Fig. 4 b 
was quantified by dividing the total cell number each day (proplatelet 
forming megakaryocytes + non proplatelet forming megakaryocytes) with 
the number of megakaryocytes at day 3.
Megakaryocyte  receptor  expression.  E13.5  (or  E12.5  where  stated) 
FLCs were cultured in SFM and TPO for 3–5 d. The cells were stained with 
CD41 or negative control for 30 min on ice before washing and analysis on 
a FACSCalibur flow cytometer (BD). Megakaryocytes were also isolated for 
PCR analysis. In brief, FLCs were cultured in TPO for 1, 2, or 3 d and 
CD41+ and propidium iodide cells were sorted on MoFlo flow cytometer. 
Sorted megakaryocytes were lysed and used for PCR.
Megakaryocyte ploidy. BM was harvested from 8–10-wk-old mice, or   
8 wk after BM reconstitution, and megakaryocyte ploidy was studied with 
propidium iodide as previously described (Kruse et al., 2009).
Serum TPO.  Serum TPO  levels  were  measured  using  the  Quantikine 
Mouse TPO Immunoassay kit (R&D Systems) according to the manufactur-
er’s instructions.
Caspase activity and viability assays. Megakaryocytes were harvested 
from BSA gradients, counted, and reseeded in SFM with TPO into 96-well 
plates, and then returned to the 37°C incubator after the addition of ABT-
737 (5 µM), etoposide (50 µM), STS (10 µM), Q-VD-OPh (50 µM), or ve-
hicle controls DMSO and ethanol if not otherwise stated. Caspase-Glo 3/7 
reagents (Promega) were added to the cells after 5 h. The luminescence of 
each sample was determined in a plate-reading LumiSTAR Galaxy lumino-
meter (BMG Labtech) as directed by manufacturer. Alternatively, Celltiter 
Glo reagents (Promega) were added after 24 h to determine cell viability by 
measuring ATP levels.
Video microscopy. Megakaryocytes were generated as detailed in the pro-
platelet formation assay and transferred to optically transparent ibiTreat tissue 
culture treated sterile µ-slide 8-well (Ibidi) or 96-well optical bottom plates 
(Nunc). Experiments were performed on a Live Cell Observer with a fully 
motorized Axiovert 200 inverted microscope (Carl Zeiss, Inc.) driven by the 
Axiovision 4.7 software (Carl Zeiss, Inc.). Cells were maintained on the stage 
within a humidified chamber at 37°C and 5% CO2. Time-lapse images were 
acquired for 24 h with an AxioCam MRm camera (Carl Zeiss, Inc.) using a 
20×/0.8  objective.  Some  experiments  were  performed  with  a  0.63×   
C-mount in place of the 1× C-mount to increase the camera field of view. 
In some experiments, CaCl2 (0.5 mM) and Alexa Fluor–488 conjugated   
Annexin V (1/100) were added immediately before commencing time-
lapse images.
more likely scenario is that polyploidization, proplatelet for-
mation, and platelet shedding generate acute proapoptotic 
stresses within the megakaryocyte, which multiple Bcl-2 fam-
ily prosurvival proteins are required to resist. Loss of Bcl-xL is 
enough to disturb the pro- and antiapoptotic balance. It will 
be interesting to see whether deletion of Mcl-1 and Bcl-2 in 
megakaryocytes  results  in  a  similar  phenotype.  Given  that 
agents specifically targeting Bcl-2 family prosurvival proteins 
are currently being developed for use in a range of human 
malignancies (Leber et al., 2010; Petros et al., 2010; Wilson   
et al., 2010; Roberts et al., In Press), it will be important to un-
derstand the contribution they make to the development and 
survival of the megakaryocyte lineage.
MATERIALS AND METHODS
Animals. Bak (Lindsten et al., 2000), Bax (Knudson et al., 1995) and Bcl-x 
(Motoyama et al., 1999) knockout,  Bcl-x (Rucker et al., 2000) and  Bax 
(Takeuchi et al., 2005) floxed, Pf4-Cre (Tiedt et al., 2007), and UBC-GFP 
(Schaefer et al., 2001) transgenic mice have been previously described. All 
mutations had been backcrossed to wild-type C57BL/6 at least 10 genera-
tions before this study. Chimeric animals in which the hematopoietic system 
was reconstituted with Bak/ Bax/ FLCs were generated as previously 
described (Schoenwaelder et al., 2009). All animal experiments complied 
with the regulatory standards of, and were approved by, the Walter and Eliza 
Hall Institute (WEHI) Animal Ethics Committee.
Materials. Biotin N-hydroxy-succinimide ester (NHS-biotin), DMSO, thi-
azole orange, propidium iodide, and STS were purchased from Sigma-Aldrich. 
ABT-737 was provided by Abbott Laboratories. Q-VD-OPh was purchased 
from Alexis, Z-VAD (OMe)-FMK was purchased from MERCK Chemicals 
Ltd., Carboplatin was purchased from Pfizer, and Etoposide was obtained from 
Mayne Pharma Pty Ltd. Enhanced chemiluminescence system (ECL; Millipore), 
protease inhibitor cocktail, Complete (Roche), 4–12% Bis-Tris gels (NuPAGE; 
Invitrogen), and Spherotech calibration beads 3.5–4.0 µm (Spherotech Inc.).
Antibodies. X488, fluorescently conjugated -GPIb (Xia.G5), -GPIX (Xia.
B4), and -GPVI (JAQ1) were obtained from Emfret Analytics GmbH and 
Co.  KG;  FITC-,  PE-,  or  APC-conjugated  anti–mouse,  CD41  (clone 
MWReg30), TER-119, CD45.1 (A20), CD45.2, CD45R/B220 (RA3-6B2), 
fluorescently conjugated streptavidin, Annexin  V, nonconjugated mouse anti–
Bcl-xl (clone 44), and mouse anti–Bcl-2 (clone 7) were purchased from   
BD; rabbit polyclonal anti-bak, anti–-tubulin, and anti-actin-HRP were 
obtained from Sigma-Aldrich; rabbit polyclonal anti-bax were from (Milli-
pore);  and  rat  anti-Mcl-1  (clone  19C4-15)  was  obtained  from WEHI 
(Parkville, Australia) mAb Facility.
Hematology. Automated cell counts were performed on blood collected 
from  the  retroorbital  plexus  into  Microtainer  tubes  containing  EDTA 
(Sarstedt), using an Advia 2120 hematological analyser (Siemens). Platelet 
counts in diluted whole blood were determined by flow cytometry with 
Sphero blank calibration particles (3.5–4.0 µm; Spherotech Inc.) and gating 
on CD41+ve and TER-119-ve cells. Megakaryocytes were counted manually 
in sections of sternum and spleen stained with hematoxylin and eosin with a 
minimum of 10 high power fields (200×) analyzed. Peripheral blood smears 
were stained with May Grunwald Giemsa. Hematopoietic progenitors were 
cultured as previously described (Alexander et al., 1996). Acute thrombocyto-
penia was induced by antiplatelet serum and assessed as previously described 
(Mason et al., 2007).
Megakaryocyte culture from fetal livers and BM. E13.5 embryos (or 
E12.5 when indicated) were harvested into cold DME Kelso, 10% FCS. Fetal 
livers were dissected out, and cell suspensions were prepared in PBS. BM was 2028 Role of mitochondrial apoptosis in megakaryocytes | Josefsson et al.
(Dowling et al., 2010). Statistical uncertainty was assessed using a Monte-Carlo 
bootstrap resampling technique (20 estimates of the production rate are plot-
ted, horizontal line is the median; Chernick, 1999; Dowling et al., 2010).
Statistical analyses. Statistical significance between two treatment groups 
was analyzed using an unpaired Student’s t test with two-tailed p-values. 
One-way ANOVA with Boferroni’s multiple comparison test was applied 
where appropriate (GraphPad Prism Software). *, P < 0.05; **, P < 0.005; 
***, P < 0.0001 or as otherwise stated. Data are presented as mean ± SEM 
or SD (where indicated).
Online supplemental material. Fig. S1 shows hematopoietic analysis of 
Bak/Bax BM chimeric mice. Fig. S2 shows characterization of the hemato-
poietic compartment in mice deficient in Bcl-x in the megakaryocytic lineage. 
Fig. S3 displays transmission electron microscope images of BM megakaryo-
cytes lacking Bcl-x. Fig. S4 shows increased viability of Bak/Bax-deficient 
BM-derived megakaryocytes in response to apoptotic stimuli. Videos 1 and 
2 show proplatelet formation by Bcl-xfl/fl control or Bcl-xPf4/Pf4 megakaryo-
cytes, respectively. Videos 3 and 4 show PS exposure visualized by Annexin 
V-Alexa Fluor 488 in green during proplatelet formation by Bcl-x+/+ control 
or Bcl-xPf4/Pf4 megakaryocytes, respectively. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20110750/DC1.
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